October 29, 2024
Geographic Atrophy Articles
October 18, 2024
Pegcetacoplan an Effective Treatment for Subfoveal GA
By Jim Gallagher, senior managing editor
October 11, 2024
My Approach to Patient Education With Avacincaptad Pegol Treatment
By Ketan G. Laud, MD
September 26, 2024
Validating Patient Concerns Regarding Geographic Atrophy and Treatment
By Priya Vakharia, MD
September 5, 2024
Anti-complement Injections for Geographic Atrophy: A Look at the Patient and Provider Experience in my Clinic
By Tanuj Banker, MD
July 25, 2024
Ellipsoid Zone Integrity at Baseline Predicts Geographic Atrophy Progression Rate
July 1, 2024
First Patient Dosed in Inflammasome GA Clinical Trial
By Rochelle Nataloni, contributing writer
July 1, 2024
Blue-light IOLs Reduce Progression of Macular Atrophy, But Not Incidence
By Rochelle Nataloni, contributing writer
July 1, 2024
New ARCHER ANX007 in GA Treatment Findings Presented at ARVO
By Rochelle Nataloni, contributing writer
July 1, 2024
Clinical Trial Update July/August 2024
June 27, 2024
Myth Busting Geographic Atrophy Treatment Options
By Priya Vakharia, MD
June 13, 2024
Patient Selection, Treatment Options, and Beyond With Complement Cascade Inhibitors for GA
By Daniel K. Bennett, MD
June 1, 2024
Ocugen Announces Milestones in OCU410 and OCU400 Clinical Trials
By Rochelle Nataloni, contributing writer
June 1, 2024
ARCHER Trial Data Indicate ANX007 Protects Against GA Vision Loss
By Jim Gallagher, senior managing editor
June 1, 2024
Controversies in Care: Chlorhexidine as an Alternative to Povidone-iodine for Antisepsis Before Intravitreal Injection
By Michael Colucciello, MD, Jason Fan, MD, PhD, Harry W. Flynn Jr., MD, et al.
June 1, 2024
Clinical Trial Update June 2024
May 1, 2024
Clinical Trial Update May 2024
April 25, 2024
How to Optimize the Geographic Atrophy Patient Experience
By Priya Vakharia, MD
April 1, 2024
Upfront: Innovations in VEGF Inhibition Delivery
By Peter K. Kaiser, MD
April 1, 2024
Clinical Trial Update April 2024
April 1, 2024
Subspecialty News April 2024
By Rochelle Nataloni, contributing writer
March 26, 2024
Geographic Atrophy: Patient Conversations, Pearls, and Office Workflows
By Rishabh Gupta, MD, Mathew W. MacCumber, MD, PhD, Vivek Chaturvedi, MD
March 8, 2024
Office Workflow Challenges With Anti-complement Therapeutics
By Priya Vakharia, MD
March 1, 2024
Clinical Trial Update March 2024
March 1, 2024
Clinical Trial Download: Longer-term Data on New Treatments for Geographic Atrophy
By Yasha Modi, MD , Vaidehi S. Dedania, MD, Talia R. Kaden, MD
March 1, 2024
Considerations in Management of Dry AMD
By Karen W. Jeng-Miller, MD, MPH
March 1, 2024
Imaging Features That Portend Development of Geographic Atrophy
By Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, Zhichao Wu, BAppSc (Optom), PhD
March 1, 2024
Subspecialty News March 2024
By Rochelle Nataloni, contributing writer
January 1, 2024
Artificial Intelligence to Manage the AMD Burden
By William Haseltine, PhD, Kim Hazel, MPH
January 1, 2024
Insightful Imaging for Geographic Atrophy
By Brian Solinsky, MD, Eliza Broadbent, BS, Elias Siltanen, BS, et al.
January 1, 2024
Subspecialty News January/February 2024
By Rochelle Nataloni, contributing writer
January 1, 2024
Show Daily Coverage From the American Academy of Ophthalmology 2023 Annual Meeting
By Steve Lenier
January 1, 2024
Clinical Trial Update January/February 2024
January 1, 2024
Therapies for Geographic Atrophy: Safety First
By Hashem Ghoraba, Sumit Sharma, MD
November 1, 2023
SUBSPECIALTY NEWS: Ryzumvi approved, positive gene therapy data, Syfovre receives J code, and more.
By Rochelle Nataloni, contributing writer
November 1, 2023
NEW PRODUCT APPLICATIONS: Drug Slows the Progression of Geographic Atrophy
By Karen Appold, contributing writer
November 1, 2023
Clinical Trial Update November/December 2023
November 1, 2023
The Role of Multimodal Imaging in Geographic Atrophy Diagnosis and Monitoring
By Mustafa Iftikhar, MD, Lejla Vajzovic, MD, FASRS
October 1, 2023
SUBSPECIALTY NEWS: Biosimilar FDA application hits roadblock, Apellis provides guidance on Syfovre use, and more.
By Rochelle Nataloni, contributing writer
October 1, 2023
NEW PRODUCT APPLICATIONS: Optos Retinal Imaging System Offers New Color Modality
By Karen Appold, contributing writer
October 1, 2023
Clinical Trial Update October 2023
October 1, 2023
Clinical Pearls for Newly Approved Treatments for GA
By Aamir A. Aziz, BS, Carl Danzig, MD
September 1, 2023
Glycoimmune Therapy as a Novel Treatment Approach for Geographic Atrophy
By Sophie J. Bakri, MD, MBA, Jeffrey S. Heier, MD, Arshad M. Khanani, MD, MA, FASRS, et al.
September 1, 2023
SUBSPECIALTY NEWS: Izervay FDA approval, ReST committee updates on Syfovre, and more.
By Rochelle Nataloni, contributing writer
September 1, 2023
Clinical Trial Update September 2023
August 7, 2023
Iveric Bio's Izervay Receives FDA Approval as Treatment for Geographic Atrophy
By Jennifer Ford, senior managing editor
July 1, 2023
SUBSPECIALTY NEWS: Mydriasis spray approved, laser and imaging devices cleared, new AI technology, and more.
By Rochelle Nataloni, contributing writer
July 1, 2023
CONTROVERSIES IN CARE: Treatment of Geographic Atrophy
By Michael Colucciello, MD, Carl D. Regillo, MD, FACS, Demetrios G. Vavvas, MD, PhD, et al.
July 1, 2023
Clinical Trial Update July/August 2023
June 1, 2023
SUBSPECIALTY NEWS: New product launches in laser and surgery, progress on clinical trials in dry AMD, and more.
By Rochelle Nataloni, contributing writer
June 1, 2023
Clinical Trial Update June 2023
May 1, 2023
Home Monitoring for Neovascular AMD Conversion
By SIDNEY A. SCHECHET, MD
May 1, 2023
SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more.
By Rochelle Nataloni, contributing writer
May 1, 2023
NEW PRODUCT APPLICATIONS: The First Drug to Treat Geographic Atrophy Debuts
By Karen Appold, contributing writer
May 1, 2023
Clinical Trial Update May 2023
April 1, 2023
Retina Clinic Considerations in the Era of Treatment for Advanced Dry AMD
By Yingna Liu, MD, Roger A. Goldberg, MD, MBA
April 1, 2023
Connecting With Patients About Geographic Atrophy
By David S. Liao, MD, David S. Boyer, MD
April 1, 2023
UPFRONT: The Beginning of Geographic Atrophy Treatment
By Peter K. Kaiser, MD
April 1, 2023
Clinical Trial Update April 2023
March 1, 2023
Gene Therapy for Dry AMD
By Ehsan Rahimy, MD, Austen N. Knapp, MD
March 1, 2023
Current Challenges in Gene Therapy Trials
By Glenn C. Yiu, MD, PhD, Arshad M. Khanani, MD, MA, FASRS, Kathryn L. Pepple, MD, PhD
March 1, 2023
SUBSPECIALTY NEWS: First drug approved for ROP, PDT laser approved, inequities in ophthalmology research, and more.
By Rochelle Nataloni, contributing writer
March 1, 2023
Clinical Trial Update March 2023
February 1, 2023
Complement Inhibition in Geographic Atrophy
By William Carrera, MD, MS, Jeffrey S. Heier, MD
February 1, 2023
Current Terminology for Geographic Atrophy Pathology
By Glenn J. Jaffe, MD
February 1, 2023
Imaging Modalities for Geographic Atrophy
By Sheena Khanna, MD, Jordan A. Sugarman, MD, SriniVas R. Sadda, MD
February 1, 2023
Treatment of Geographic Atrophy by Anatomic Location
By Anna Marmalidou, MD, Antonio Yaghy, MD, Nadia K. Waheed, MD, MPH
February 1, 2023
Novel Targets for Geographic Atrophy
By Rishi P. Singh, MD, Neha Sharma, MD, MPH
February 1, 2023
Practice Considerations Regarding Treatment of Geographic Atrophy
By Daniel Su, MD, David S. Boyer, MD
February 1, 2023
UPFRONT: Evolution of Retina Clinical Trials to Target Geographic Atrophy
By Peter K. Kaiser, MD
February 1, 2023
GUEST EDITORIAL: At the Brink of a Dry AMD Revolution
By Eleonora Lad, MD, PhD
February 1, 2023
SUBSPECIALTY NEWS: Methotrexate for vitreoretinal lymphoma, drugs for retinitis pigmentosa, AI technology in retina, and more.
By Rochelle Nataloni, contributing writer
January 1, 2023
SUBSPECIALTY NEWS: Progress toward GA drug approval, new gene therapy data, and more.
By Rochelle Nataloni, contributing writer
January 1, 2023
CODING Q&A: Intravitreal Medications for Geographic Atrophy
By Suzanne L. Corcoran, COE
January 1, 2023
Clinical Trial Update January/February 2023
November 1, 2022
Remote Monitoring to Track Fellow Eye AMD Progression
By Miguel A. Busquets, MD
November 1, 2022
SUBSPECIALTY NEWS: New data presented at AAO in dry AMD, ocular oncology, gene therapy, and more.
By Rochelle Nataloni, contributing writer
November 1, 2022
CONTROVERSIES IN CARE: Examining the Evidence for Macular Atrophy as a Complication of Anti-VEGF Therapy for Wet AMD
By Michael Colucciello, MD
November 1, 2022
Clinical Trial Update November/December 2022
October 1, 2022
SUBSPECIALTY NEWS: FDA approves Cimerli, GATHER2 GA trial meets primary endpoint, and more.
By Rochelle Nataloni, contributing writer
October 1, 2022
Clinical Trial Update October 2022
September 1, 2022
SUBSPECIALTY NEWS: Pegcetacoplan gets priority review, Eva Nexus injector cleared, Eylea extended dosing under review, and more.
By Rochelle Nataloni, contributing writer
September 1, 2022
Clinical Trial Update September 2022
August 1, 2022
SUBSPECIALTY NEWS: Data presented on THR-149 and THR-687 for DME, pegcetacoplan NDA submitted, AREDS2 benefit confirmed, and more.
By Rochelle Nataloni, contributing writer
August 1, 2022
Clinical Trial Update Special Edition 2022
July 1, 2022
Potential Implications of Silicone Oil From Syringes
By Gustavo B. Melo, MD, PhD, FASRS
July 1, 2022
SUBSPECIALTY NEWS: RetinAI gets FDA clearance, suprachoroidal therapy update, GA trial data, and more.
By Rochelle Nataloni, contributing writer
July 1, 2022
Clinical Trial Update July/August 2022
June 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy quality-of-life survey, Xipere launch, ophthalmic bevacizumab FDA application, and more.
By Rochelle Nataloni, contributing writer
June 1, 2022
Clinical Trial Update June 2022
May 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy lesion growth slowed with pegcetacoplan, new data on extended-duration therapies, and more.
By Rochelle Nataloni, contributing writer
May 1, 2022
Clinical Trial Update May 2022
April 1, 2022
Early-phase Drugs in Development for Dry AMD
By William Carrera, MD, MS, Roger A. Goldberg, MD, MBA
April 1, 2022
Treating AMD at the Intermediate Level
By Carla Danese, MD, PAOLO LANZETTA, MD
April 1, 2022
SUBSPECIALTY NEWS: FDA approves uveal melanoma treatment, sepofarsen fails to meet endpoints, and more.
By Rochelle Nataloni, contributing writer
April 1, 2022
Clinical Trial Update April 2022
March 1, 2022
SUBSPECIALTY NEWS: Results in suprachoroidal trial, RNA therapy for RP, Beovu in DME, and more.
By Rochelle Nataloni, contributing writer
March 1, 2022
Clinical Trial Update March 2022
January 1, 2022
Clinical Trial Update January/February 2022
Advertisement
Recommendations
Advertisement